Pasithea Therapeutics (KTTA) Payables (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Payables of $1.5 million for Q1 2026, up 31.68% sequentially from $1.1 million in Q4 2025, and up 12.34% YoY from $1.3 million in Q1 2025.
Pasithea Therapeutics (KTTA) Payables (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Payables for 7 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Payables rose 12.34% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 12.34% YoY) and the FY2025 annual result came in at $1.1 million, up 1.0% from the prior year.
- Payables rose to $1.5 million in Q1 2026 per KTTA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Payables peaked at $2.6 million in Q4 2023 and troughed at $433684.0 in Q1 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2024: Payables jumped 236.42% in 2023, then sank 64.67% in 2024.
- Over 5 years, Payables stood at $1.5 million in 2022, then soared by 71.3% to $2.6 million in 2023, then slumped by 56.12% to $1.1 million in 2024, then grew by 1.0% to $1.1 million in 2025, then jumped by 31.68% to $1.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $1.5 million, $1.1 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 660,397.00 |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 2.55 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 1.26 Mn |
| Jun 30, 2022 | 848,694.00 |
| Mar 31, 2022 | 433,684.00 |
| Dec 31, 2021 | 447,280.00 |
| Sep 30, 2021 | 528,096.00 |
| Dec 31, 2020 | 6,603.00 |